| scholarly article | Q13442814 |
| P50 | author | Andrea LaCroix | Q28360453 |
| William T. Longstreth | Q123220049 | ||
| P2093 | author name string | Phillip D Swanson | |
| Gary M Franklin | |||
| Harvey Checkoway | |||
| Terri Smith-Weller | |||
| Brad A Racette | |||
| Thanh G N Ton | |||
| Jessica I Lundin | |||
| P2860 | cites work | The Impact of Gender and Estrogen on Striatal Dopaminergic Neurotoxicity | Q23912105 |
| Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial | Q27860743 | ||
| Nonsteroidal anti-inflammatory drugs and risk of Parkinson's disease | Q28195845 | ||
| Short-term effects of high-dose 17beta-estradiol in postmenopausal PD patients: a crossover study | Q28369296 | ||
| Impact of progestins on estrogen-induced neuroprotection: synergy by progesterone and 19-norprogesterone and antagonism by medroxyprogesterone acetate | Q28578932 | ||
| Postmenopausal estrogen use affects risk for Parkinson disease | Q30433773 | ||
| Reliability of Group Health Cooperative automated pharmacy data by drug benefit status | Q30991208 | ||
| Female reproductive factors, menopausal hormone use, and Parkinson's disease | Q33756791 | ||
| The effects of postmenopausal hormone therapy on serum estrogen, progesterone, and sex hormone-binding globulin levels in healthy postmenopausal women | Q33838504 | ||
| Neuroprotective effects of estrogens: potential mechanisms of action | Q33922344 | ||
| Parkinson's disease and parkinsonism in a longitudinal study: two-fold higher incidence in men. ILSA Working Group. Italian Longitudinal Study on Aging. | Q33925972 | ||
| Neuroprotection by estradiol. | Q34065270 | ||
| ??? | Q64779263 | ||
| ??? | Q64900602 | ||
| Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity | Q34201593 | ||
| Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis | Q34356168 | ||
| Hysterectomy, menopause, and estrogen use preceding Parkinson's disease: an exploratory case-control study. | Q34464847 | ||
| Association of coffee and caffeine intake with the risk of Parkinson disease | Q34508881 | ||
| Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. | Q34516364 | ||
| Parkinson's disease risks associated with cigarette smoking, alcohol consumption, and caffeine intake | Q34522327 | ||
| A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease | Q34526685 | ||
| Estrogen anti-inflammatory activity in brain: a therapeutic opportunity for menopause and neurodegenerative diseases | Q34784469 | ||
| Estrogens and menopause: pharmacology of conjugated equine estrogens and their potential role in the prevention of neurodegenerative diseases such as Alzheimer's | Q35207804 | ||
| Mechanisms of progesterone-induced neuroprotection | Q36197934 | ||
| Reproductive factors, exogenous estrogen use, and risk of Parkinson's disease | Q37362137 | ||
| Oestrogen receptors and signalling pathways: implications for neuroprotective effects of sex steroids in Parkinson's disease | Q37905899 | ||
| The effect of estrogen in a man with Parkinson's disease and a review of its therapeutic potential | Q38102751 | ||
| Sex differences in Parkinson's disease and other movement disorders | Q38200393 | ||
| Duration of estrogen replacement therapy in relation to the risk of incident myocardial infarction in postmenopausal women | Q38504402 | ||
| Neuroprotective properties of 17beta-estradiol, progesterone, and raloxifene in MPTP C57Bl/6 mice | Q43635677 | ||
| Risk tables for parkinsonism and Parkinson's disease. | Q44309519 | ||
| Caffeine, postmenopausal estrogen, and risk of Parkinson's disease | Q44357392 | ||
| Estradiol in the striatum: effects on behavior and dopamine receptors but no evidence for membrane steroid receptors | Q44552900 | ||
| Effect of reproductive factors and postmenopausal hormone use on the risk of Parkinson disease. | Q45933973 | ||
| Anti-aggregation and fibril-destabilizing effects of sex hormones on alpha-synuclein fibrils in vitro | Q46087126 | ||
| Effects of estrogens on striatal damage after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in male and female mice | Q46405442 | ||
| Oestrogens prevent loss of dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) in substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice | Q46596326 | ||
| Characterization and implications of estrogenic down-regulation of human catechol-O-methyltransferase gene transcription | Q47952194 | ||
| Effect of chronic estradiol and progesterone treatments of ovariectomized rats on brain dopamine uptake sites | Q48291787 | ||
| 17 beta-Estradiol at a physiological dose acutely increases dopamine turnover in rat brain | Q48436698 | ||
| Estrogen as a neuromodulator of MPTP-induced neurotoxicity: effects upon striatal dopamine release | Q48643724 | ||
| Exposure to estrogen and women's risk for Parkinson's disease: a prospective cohort study in Denmark. | Q50558296 | ||
| Nicotine alters the expression of molecular markers of endocrine disruption in zebrafish. | Q50788448 | ||
| Risk of Parkinson disease in women: effect of reproductive characteristics. | Q51940269 | ||
| Direct effect of 17 beta-estradiol on striatum: sex differences in dopamine release | Q68719976 | ||
| Increased dopamine receptor sensitivity after estrogen treatment using the rat rotation model | Q70649154 | ||
| Time trends in the incidence of parkinsonism in Olmsted County, Minnesota | Q74364988 | ||
| P433 | issue | 13 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1631-1636 | |
| P577 | publication date | 2014-09-25 | |
| P1433 | published in | Movement Disorders | Q1486418 |
| P1476 | title | Formulations of hormone therapy and risk of Parkinson's disease | |
| P478 | volume | 29 |
| Q28079898 | Estrogenic Endocrine Disrupting Chemicals Influencing NRF1 Regulated Gene Networks in the Development of Complex Human Brain Diseases |
| Q36995708 | Etiologic Framework for the Study of Neurodegenerative Disorders as Well as Vascular and Metabolic Comorbidities on the Grounds of Shared Epidemiologic and Biologic Features |
| Q92576096 | Female Sex and Brain-Selective Estrogen Benefit α-Synuclein Tetramerization and the PD-like Motor Syndrome in 3K Transgenic Mice |
| Q49817768 | Lifetime exposure to estrogen and progressive supranuclear palsy: Environmental and Genetic PSP study |
| Q38969930 | Menopause and Parkinson's disease. Interaction between estrogens and brain renin-angiotensin system in dopaminergic degeneration. |
Search more.